IMUC logo

EOM Pharmaceuticals Holdings OTCPK:IMUC Stock Report

Last Price

US$0.27

Market Cap

US$31.0m

7D

23.9%

1Y

-21.7%

Updated

25 Mar, 2024

Data

Company Financials

EOM Pharmaceuticals Holdings, Inc.

OTCPK:IMUC Stock Report

Market Cap: US$31.0m

IMUC Stock Overview

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases.

IMUC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

EOM Pharmaceuticals Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for EOM Pharmaceuticals Holdings
Historical stock prices
Current Share PriceUS$0.27
52 Week HighUS$0.40
52 Week LowUS$0.15
Beta1.38
1 Month Change-8.67%
3 Month Change29.20%
1 Year Change-21.74%
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.29%

Recent News & Updates

Recent updates

Shareholder Returns

IMUCUS BiotechsUS Market
7D23.9%-0.06%2.1%
1Y-21.7%9.8%30.4%

Return vs Industry: IMUC underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: IMUC underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is IMUC's price volatile compared to industry and market?
IMUC volatility
IMUC Average Weekly Movement45.8%
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: IMUC's share price has been volatile over the past 3 months.

Volatility Over Time: IMUC's weekly volatility has decreased from 55% to 46% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20204Irach Taraporewalahttps://www.eompharma.com

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases.

EOM Pharmaceuticals Holdings, Inc. Fundamentals Summary

How do EOM Pharmaceuticals Holdings's earnings and revenue compare to its market cap?
IMUC fundamental statistics
Market capUS$31.02m
Earnings (TTM)-US$5.13m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMUC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$5.13m
Earnings-US$5.13m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.045
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-81.8%

How did IMUC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.